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tRNA3
Lys is a primer for reverse transcription in human immunodeficiency virus type 1 (HIV-1), and the
anticodon of tRNA3
Lys has been implicated in playing a role in both its placement onto the HIV-1 genome and
its interaction with HIV-1 reverse transcriptase (RT). In this work, the anticodon in a tRNA3
Lys gene was
changed from UUU to CUA (tRNA3
LysSu1) or, in addition, G-73 was altered to A (tRNA3
LysSu1G73A). COS-7
cells were transfected with either wild-type or mutant tRNA3
Lys genes, and both the wild-type and mutant
tRNA3
Lys produced were purified by using immobilized tRNA-specific hybridization probes. Each mutant
tRNA3
Lys was tested for its ability to prime reverse transcription in vitro, either alone or in competition with
wild-type tRNA3
Lys. Short RT extensions of wild-type and mutant tRNA3
Lys could be distinguished from each
other by their different mobilities in one-dimensional single-stranded conformation polymorphism polyacryl-
amide gel electrophoresis. These reverse transcription products show that heat-annealed tRNA3
LysSu1 has the
same ability as heat-annealed wild-type tRNA3
Lys to prime RT and competes equally well with wild-type tRNA3
Lys
for priming RT. tRNA3
LysSu1G73A has 60% of the wild-type ability to prime RT but competes poorly with
wild-type tRNA3
Lys for priming RT. However, the priming abilities of wild-type and mutant tRNA3
Lys are quite
different when in vivo-placed tRNA is examined. HIV-1 produced in COS cells transfected with a plasmid
containing both the HIV-1 proviral DNA and DNA coding for tRNA3
LysSu1 contains both endogenous, cellular
wild-type tRNA3
Lys and mutant tRNA3
Lys. When total viral RNA is used as the source of primer tRNA placed
onto the genomic RNA in vivo, only wild-type tRNA3
Lys is used as a primer. If the total viral RNA is first heated
and exposed to hybridizing conditions, then both the wild-type and mutant tRNA3
Lys act as primers for RT.
These results indicate that the tRNA3
LysSu1 packaged into the virions is unable to act as a primer for RT, and
a model is proposed to explain the disparate results between heat-annealed and in vivo-placed primer tRNA.
During retroviral replication, the synthesis of minus-strand
strong-stop DNA by reverse transcriptase (RT) is primed by a
cellular tRNA. The 39-terminal 18 to 20 nucleotides in the
tRNA bind to a complementary region at the 59 portion of the
RNA genome termed the primer binding site (PBS). In hu-
man immunodeficiency virus type 1 (HIV-1), the 18-nucleo-
tide sequence comprising the PBS indicates that tRNA3
Lys is
the primer for the RT in this virus (20). In addition to the
tRNA3
Lys-PBS interaction, it has been postulated, on the basis
of chemical and enzymatic probing and computer modeling,
that additional interactions occur between regions upstream of
the HIV-1 PBS and the D, TCC, and anticodon loops of the
tRNA3
Lys (11, 12). For example, it has been proposed that
during the initiation of reverse transcription, a specific inter-
action occurs between an A-rich loop located upstream of the
PBS in the HIV-1 genome and the anticodon of tRNA3
Lys and
that dethiolation of mcm5S2U at position 34 in the anticodon
of tRNA3
Lys destabilizes this interaction (12). An interaction
between regions upstream of the PBS and the TCC loop has
also been proposed to exist in non-HIV retrovirus (1, 2). Fur-
thermore, in vitro studies using platinum cross-linking (5, 6)
and nuclease digestion studies (21, 26) have also indicated that
HIV-1 RT interacts with the D, anticodon, and TCC loops of
tRNA3
Lys.
These reports, therefore, suggest that the anticodon loop of
tRNA3
Lys interacts with both the genomic template and RT. In
this work, we tested the ability of a mutant tRNA3
Lys to function
as a primer tRNA for HIV-1 RT. The anticodon of this tRNA
has been altered from SUU (where S 5 mcm5S2U) to the
suppressor anticodon CUA. We have previously shown that
modifying the tRNA3
Lys anticodon from SUU to CUA does not
affect its ability to be selectively packaged into HIV-1 during
viral assembly in vivo (10), even though it is likely that RT
sequences within Pr160gag-pol are probably responsible for car-
rying the tRNA into the virus (17). The insensitivity of select
packaging of the tRNA to anticodon sequence is also demon-
strated by the fact that the other major cellular tRNALys iso-
acceptor, tRNA1,2
Lys, whose anticodon is CUU, is also pack-
aged into the virion (13). In this work, we show that while
tRNA3
LysSu1 functions well as a primer for reverse transcrip-
tion when heat annealed to genomic RNA, it does not serve as
a primer when a primer tRNA3
Lys-genomic RNA template
complex made in vivo is used.
MATERIALS AND METHODS
Plasmid construction. pSVK3 is a simian virus 40-based vector (Pharmacia).
pMV104-Lys and pMV104-Lys(Su1) are plasmids containing, respectively, a
human tRNA3Lys gene fragment and a human amber suppressor tRNA3Lys gene
fragment (anticodon TTT changed to CTA). The suppressor tRNA3Lys gene was
created by site-directed mutagenesis. In addition to the sequence coding for
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tRNA, both tRNA sequences are flanked by cellular sequences, with 328 bases
at the 59 end and 379 bases at the 39 end. Both plasmids were a gift from Ye Shih
Ho, Wayne State University. pSVK3.Lys3 contains a human tRNA3Lys gene, and
pSVK3.Lys3SU1 contains a suppressor tRNA gene. The plasmids were con-
structed by removing a BamHI-EcoRI fragment from the pMV104 plasmids and
cloning this fragment in reverse orientation into the EcoRI and BamHI sites of
pSVK3.
pSVK3.Lys3Su1G73A was created by PCR mutagenesis, changing G-73 to A
in the vector pSVK3.Lys3SU1. The primers used for PCR amplification were
primer 1 (59ATACGGCTCGCGTTTGTACTGT39), primer 2 (59CCAGGGTT
CAAGTCCCTGTTCGGGCAGCATGTCTTTGCTTTTGGG39), primer 3 (59
AACAGGGACTTGAACCCTGGA39), and primer 4 (59ACCTCTCAGAGAA
GCCCATAGC39). Primer 2 introduced tRNA3Lys G-73 changed to A (under-
lined). In the first PCR amplification, fragments upstream (primer 1 and primer
2) and downstream (primer 3 and primer 4) were PCR amplified in two separate
reactions (the mixture contained 500 ng of primers, 10 ml of 103 amplification
buffer, 10 ml of 2 mM four-deoxynucleoside triphosphate [dNTP] mix, 2.5 U of
Pfu DNA polymerase [Stratagene], and H2O), using 25 cycles consisting of
denaturation at 948C for 1 min, annealing at 558C for 2 min, and elongation at
728C for 2 min. In the second PCR amplication, 50 ng of each amplified fragment
was combined with PCR mix (500 ng of primer 1 and primer 4), and PCR was
carried out for 25 cycles. The PCR products were extracted with phenol-chloro-
form and precipated with ethanol. The amplified products were digested by NarI
and SpeI, and the 386-base fragment was cloned into the NarI and SpeI sites of
pSVK3.Lys3SU1. Mutations were confirmed by DNA sequencing (Sequenase
version 2.0; United States Biochemical).
Construction of SVC21.BH10, SVC21.BH10Lys3, and SVC21.BH10SU1 was
performed as previously described (10).
Production of virus and isolation of viral RNA. The methods of production of
HIV-1 virus and isolation of viral RNA were as previously described (10).
Wild-type and mutant tRNALys purification. Wild-type and mutant tRNA3Lys
were produced in COS-7 cells transfected with the pSVK3 plasmids described
above, using the calcium phosphate transfection method as previously described
(10). Total cellular RNAs were extracted from cells by the guanidinium isothio-
cyanate procedure. The low-molecular-weight RNA fraction which contains
tRNAs was isolated by using an AX500 ion-exchange column (Macherey-Nagel)
according to the manufacturer’s directions.
Specific tRNAs can be purified by hybridizing total tRNA to immobilized
DNA probes complementary to the tRNA in question (22). In this method,
developed by H. Tsurui and colleagues, the oligonucleotide to be immobilized is
synthesized with an aminohexyl linker at the 59 end and is chemically immobi-
lized to tresylate silica. The tresylate silica is made by adding tresyl chloride
(Fuluka Chemie A.G., Buchs, Switzerland) to diol silica (Shimadzu Technore-
search Co., Kyoto, Japan). We have used this method to purify the following. For
wild-type tRNA3Lys, a 30-base DNA probe which is complementary to tRNA
bases G-44 to G-73 (CGCCCGAACAGGGACTTGAACCCTGGACCC) is
used; for tRNA3LysSu1 and tRNA3LysSu1G73A, a 28-base DNA probe which is
complementary to tRNA bases A-21 to C-49 (GGACCCTCAGATTTAGA
GTCTGATGCTCT) is used. These DNA probes are immobilized via an amino
group on the 59 terminus onto tresylate silica (kindly provided by H. Tsurui,
Juntendo University School of Medicine, Hongo, Japan). The human placental
tRNA1,2Lys used in this study was purified by standard chromatographic methods as
previously described (13). The purity of wild-type and mutant tRNA3Lys was
tested by dot blot hybridization as previously described (10). The oligonucleo-
tides used to detect the different tRNAs were 59TGGCGCCCGAACAGGG
AC39 (tRNA3Lys), 59TGGCGCCCAACGTGGGGC39 (tRNA1,2Lys), 59CCCTCA
GATTTAGAGTCTGATGC39 (tRNA3LysSu1), and 59TGGTGCCCGAACAGG
GAC39 (tRNA3LysSu1G73A).
HIV-1 RT purification. The procedures developed by Muller et al. (18) were
used to extract HIV-1 RT expressed in Escherichia coli containing plasmids
coding for the RT subunits (pRT66 and pRT51), with the following modifica-
tions: after addition of lysozyme, the cells were incubated at 378C for 30 min, and
6 M urea was used to solubilize RT in the case of RT present in unextractable
protein inclusion. The system used for purifying the heterodimeric form was the
Waters 626 liquid chromatography system, and the column was a Resources Q
column (Pharmacia LKB Biotechnology Inc.). The program used to perform the
separation consisted of 3 min of holding with Tris-HCl buffer (25 mM, pH 8.2)
at a flow rate of 1 ml/min followed by a linear increase of the NaCl concentration
from 0.0 to 0.2 M in 20 min. The eluate was collected as 1 ml per fraction. The
purity of the enzyme was confirmed by loading 10 ml of each fraction on a sodium
dodecyl sulfate-polyacrylamide gel, and the pooled fractions which contained
pRT66 and pRT51 were concentrated with a Centricon-50 concentrator (Ami-
con, Beverly, Mass.) and stored in 50% glycerol. The activity of the concentrated
enzyme was determined by RT assay (8).
tRNALys-directed primer extension. The reactions were carried out in a vol-
ume of 20 ml containing 50 mM Tris-HCl (pH 7.8), 100 mM KCl, 10 mMMgCl2,
10 mM dithiotheitol, 0.2 mM dNTP, different concentrations (,2 pmol) of
wild-type or mutant tRNA3Lys, and 2 pmol of HIV RNA (497 bases) which was
made from AccI-linearized plasmid pHIV-PBS (3) with the MEGAscript tran-
scription system (Ambion). The synthetic genomic RNA comprises the complete
R,U5 region, the PBS, leader, and part of the gag coding region. Annealing of
tRNA to genomic RNA was accomplished by heating the reaction mixture at
858C for 2.5 min, cooling it to 508C for 8 min, and stabilizing it at 378C for 10 min.
To the reaction mix were sequentially added 50 ng of HIV-1 RT, 10 U of RNasin
(Promega), and 15 mCi of [a-32P]dCTP (3,000 Ci/mmol; Dupont), and the mix
was then incubated at 378C for 1 h. After incubation, the reaction products were
precipitated with an equal volume of 2-propanol, and after resuspension of the
precipitate in loading buffer (95% formamide, 20 mM EDTA, 0.05% bromo-
phenol blue, 0.05% xylene cyanol), the samples were electrophoresed on a 6%
denaturing polyacrylamide gel.
When total viral RNA was used as the source of primer/template, 109 copies
of viral genomic RNA were used.
Quantitative determination of genomic RNA in an HIV-1 viral RNA sample.
Antisense primer A55 (59CTGCTAGAGATTTTCCACACTGAC39) was used
for primer extension to quantitate the genomic RNA (4). This primer binds to
DNA positions 612 to 635, just upstream of the PBS. To establish a standard
curve, a synthetic 497-nucleotide HIV-1 RNA fragment (3) was reverse tran-
scribed from positions 635 to 473 of the HIV genome plus 11 bases of vector
sequence, using SUPERSCRIPT II RNase H-RT (BRL-GIBCO). Viral genomic
RNA was extended from position 635 to the end of the 59 R region. Quantitation
of viral genomic RNA and synthetic genomic RNA was done by phosphor
imaging (Bio-Rad). The relative intensities of extended signals were used to
determine the concentration of genomic RNA in the viral samples by using the
standard curve (r2 5 0.9959).
Primer extension by competing wild-type and mutant tRNA3
Lys. The reaction
conditions for primer extension were modified from those described above. The
differences are that 0.5 pmol of synthetic genomic RNA was used instead of 2.0
picomol, and 0.2 mM dGTP and TTP and 0.02 mM ddATP and were used
instead of 0.2 mM dNTP, conditions which allow the primer to be extended only
six bases, which facilitates better separation between extended wild-type and
mutant tRNAs on a single-stranded conformation polymorphism (SSCP) poly-
acrylamide gel (19). The reaction was carried out in the presence of 15 mCi of
[a-32P]dCTP (3,000 Ci/mmol; Dupont). After isopropanol precipitation of the
reaction mix, the precipitate was resuspended in loading buffer (described above)
and electrophoresed in an SSCP gel (10% polyacrylamide–10% glycerol nonde-
naturing gel, 87.3 cm by 17.1 cm by 0.4 mm) and run at 48C for 22 h at 35 W, using
an SA adjustable sequencing system (BRL-GIBCO).
RESULTS
Purification of wild-type and mutant tRNA3
Lys to be tested as
primers. In this work, we tested the abilities of wild-type and
mutant tRNA3
Lys to prime reverse transcription in vitro. The
positions of the mutated bases in tRNA3
Lys are shown in Fig.
1. These tRNAs were isolated from COS-7 cells which had
been transfected with wild-type or mutant tRNA3
Lys genes. We
have used the hybridization procedure of Tsurui et al. (22) to
purify the tRNAs from the small amounts of infected cell total
tRNA available. Figure 2 shows the one-dimensional (1D)
polyacrylamide gel electrophoresis (PAGE) analysis of puri-
fied tRNALys samples, as well as the total tRNA before puri-
fication. The human placental tRNA1,2
Lys was previously purified
by more standard chromatographic methods (13). Each tRNA
sample was 39 end labeled in vitro with 32pCp and analyzed by
PAGE (11% gel). It can be seen that each tRNA sample
resolves into only one major species, and we have found that
each sample remains as one major species when resolved by
2D PAGE (data not shown).
To further test the purity of each tRNA, dot blots were
performed to test the ability of each tRNA sample to hybridize
with DNA probes specific for the different tRNALys species.
The regions on tRNA3
Lys complementary to these DNA probes
are shown in Fig. 1. The hybridization probes are shorter than
the immobilized ones used for tRNA purification and are com-
plementary either to the 39-terminal 18 nucleotides of the
tRNA (in Fig. 3, probes Lys1,2, Lys3, and G73A) or to the 23
bases which include the anticodon arm (in Fig. 3, probe Su1).
tRNA1,2
Lys and tRNA3
Lys are purified from cells containing only
these two tRNALys species as major isoacceptors, and it is clear
from Fig. 3 that these purified tRNALys samples are not cross-
contaminated. It is also clear that tRNA3
LysSu1G73A is not
contaminated with either tRNA1,2
Lys or tRNA3
Lys. While the
tRNA3
LysSu1 sample does not contain detectable tRNA1,2
Lys, we
do not have a probe which will show that this sample is free of
tRNA3
Lys, since the Lys3 probe hybridizes to both tRNAs.
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However, we will show in Fig. 5, by electrophoretic analysis,
that neither of the mutant tRNAs isolated contains detectable
wild-type tRNA3
Lys.
Abilities of wild-type and mutant tRNALys to prime reverse
transcription.We tested the abilities of the wild-type and mu-
tant tRNA3
Lys isoacceptors to prime reverse transcription of
minus-strand strong-stop DNA in vitro, using HIV-1 RT and
2 pmol of synthetic genomic RNA. Figure 4A shows the 1D
PAGE of the reaction products, while Fig. 4B shows the quan-
titation of the synthesis of the 249-bp strong-stop DNA, us-
ing phosphor imaging. It is clear from Fig. 4 that wild-type
tRNA3
Lys and tRNA3
LysSu1 have equal abilities to prime re-
verse transcription, while tRNA3
LysSu1G73A is only 60% as
efficient a primer as tRNA3
Lys. tRNA1,2
Lys is used at 10-fold-
higher concentrations than the tRNA3
Lys species and is only 3%
as efficient at priming reverse transcription as tRNA3
Lys. This
reduced ability of tRNA1,2
Lys to prime reverse transcription is
probably due to more than the imperfect matching of this
tRNA with the PBS, since recent work has indicated that even
when the PBS is altered to match the terminal 39 18 nucleo-
tides of tRNA1,2
Lys, the PBS is eventually changed back in vivo to
the sequence complementary to tRNA3
Lys (9, 15).
Ability of mutant tRNA3
Lys to compete with wild-type tRNA3
Lys
for priming of reverse transcription. The reactions represent-
ed in Fig. 4 were done with an excess of genomic RNA over the
amount of tRNA3
Lys species used but may still have been in-
sensitive to differences in the ability of each tRNA3
Lys to bind to
the genomic RNA. Therefore, Fig. 5 shows results of another
series of experiments which tested the ability of either of the
mutant tRNA3
Lys species to compete with wild-type tRNA3
Lys
for primer function under conditions of tRNA excess over
genomic RNA. We have found that the mutant tRNA3
Lys spe-
cies can be distinguished from the wild-type tRNA3
Lys by using
SSCP native gel electrophoresis at 48C, when the reverse tran-
scription extensions are limited in length. The reactions rep-
resented in Fig. 5 were carried out in the absence of dATP and
the presence of ddATP, which will result in a six-base DNA
extension of the primer tRNA by RT (the first six bases incor-
porated are, sequentially, CTGCTA). It can be seen in the first
two lanes of Fig. 5A and B that the extended mutant tRNA3
Lys
has a slower electrophoretic mobility than the extended wild-
type tRNA3
Lys. These results also indicate that the isolated
mutant tRNA3
Lys samples are not contaminated with wild-type
tRNA3
Lys. In Fig. 5A, the ratio of the two transcripts depends
on the ratio of the two primer tRNAs used, indicating that
tRNA3
LysSu1 has an equal ability to compete with wild-type
tRNA3
Lys for priming reverse transcription under conditions of
tRNA excess. This is not the case for tRNA3
LysSu1G73A, since
Fig. 5B shows that regardless of the ratio of mutant to wild-
type tRNA3
Lys, the majority of transcripts are made from wild-
type tRNA3
Lys.
These experiments also demonstrate the inhibition of re-
verse transcription at higher tRNA3
Lys concentrations, a phe-
nomenon previously reported (7). While both mutant and wild-
type tRNA3
Lys show this inhibitory property, the wild-type form
appears to be a more efficient inhibitor of reverse transcription
than either mutant tRNA.
Ability of tRNA3
LysSu1 packaged in virions to initiate re-
verse transcription. Instead of using heat-annealed tRNA as
the source of the primer for RT, we used total viral RNA
extracted from virions as the source of primer/template in an in
vitro reaction using HIV-1 RT and conditions which allow only
a six-base extension (the reaction mixture lacks dATP and
contains ddATP). We have previously shown that when COS-7
cells are transfected with a plasmid containing both HIV-1
proviral DNA and a tRNA3
Lys gene (wild type or tRNA3
LysSu1),
the plasmid-derived tRNA is packaged into the virus (10). In
the experiments shown in Fig. 6 and 7, total viral RNA was
isolated from wild-type virions and from virions containing
excess amounts of either tRNA3
Lys or tRNA3
LysSu1.
We are assuming that the tRNA3
Lys acting as a primer was
FIG. 1. Wild-type and mutant tRNA3Lys. The positions in tRNA3Lys of the
mutations used in this study are shown. tRNA3LysSu1 has the SUU anticodon
altered to CUA, and tRNA3LysSu1G73A, in addition to the mutant anticodon,
also has G-73 changed to A. The sequences between the arrows show the regions
of tRNA hybridized with the DNA probes used in Fig. 3 to detect the different
tRNAs. Thus, the Lys3 and G73A probes are complementary to the tRNA region
between arrows 3 and 4, while the Su1 probe is complementary to the tRNA
region between arrows 1 and 2. The Lys1,2 probe is complementary to the
39-terminal 18 nucleotides of tRNA1,2Lys, which differs from the same region in
tRNA3Lys at five base positions.
FIG. 2. 1D PAGE of purified tRNALys isoacceptors. Wild-type tRNA3Lys and
mutant tRNA3Lys (tRNA3LysSu1 and tRNA3LysSu1G73A) were purified by hybrid-
izing cellular tRNA to immobilized DNA probes specific for the tRNA. tRNA1,2Lys
was purified by more standard chromatographic methods used for tRNA puri-
fication. The tRNAs were 39 end labeled with 32pCp and electrophoresed on an
11% denaturing polyacrylamide gel.
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placed upon the genome in vivo, since we are unable to anneal
exogenous tRNA3
Lys to synthetic or native genomic RNA under
the reaction conditions used here (data not shown). In addi-
tion, we have recently identified the in vivo-placed primer
tRNA in wild-type virions as tRNA3
Lys by comparing the T1
digestion pattern of the tRNA labeled under these conditions
with that of purified human placental tRNA3
Lys heat annealed
to synthetic genomic RNA and similarly labeled by reverse
transcription (16). Figure 6 shows the SSCP PAGE pattern of
the reverse transcription products. Equal amounts of genomic
RNA were used in all reactions. Since the data in Fig. 3 indi-
cate that excess wild-type or mutant tRNA3
Lys can inhibit in
vitro reverse transcription, we performed these experiments
with increasing amounts of RT to overcome this inhibition.
The use of total viral RNA isolated from wild-type virus
(SVC21.BH10) shows no evidence of RT inhibition, while the
use of total viral RNA isolated from virus containing either
excess wild-type tRNA3
Lys (SVC21.BH10Lys3) or tRNA3
LysSu1
(SVC21.BH10SU1) does. Increasing concentrations of RT
lead to increased synthesis of RT-extended products in both
cases. It is clear that in the virus containing both wild-type
and mutant tRNA3
Lys, only the wild-type tRNA3
Lys is used as
the primer tRNA. It can also be seen that the amount of
product made from RNA isolated from the SVC21.BH10SU1
virus is less than that made from RNA isolated from the
SVC21.BH10Lys3 virions. The last two lanes in Fig. 6 show the
RT extensions from heat-annealed tRNA3
LysSu1 and tRNA3
Lys,
respectively.
Although tRNA3
LysSu1 does not act as a primer, it is present
in the SV21.BH10SU1 virion RNA. This is shown in Fig. 7, in
which total viral RNA from mutant (SVC21.BH10SU1) or
wild-type (SV21.BH10) virions was exposed to heat-annealing
conditions. RT extension from both wild-type and mutant
tRNA3
Lys is then seen for SVC21.BH10SU1 but not for
SV21.BH10. These reactions were performed in the presence
of excess synthetic HIV genomic RNA to ensure the opportu-
nity for all primer tRNAs present to hybridize and prime RT.
As a result, much less (about 1/10) total viral RNA than used
in Fig. 6 is required to obtain detectable reaction products, and
inhibition of reverse transcription by excess primer tRNA,
using 50 ng of RT per reaction, is not a problem.
DISCUSSION
In this work, we show that a mutant tRNA3
Lys whose anti-
codon has been changed from SUU to CUA can still compete
well with wild-type tRNA3
Lys as a primer for initiating reverse
transcription when heat annealed to the template in vitro. This
competitive assay is more sensitive for detecting differences in
priming efficiencies than the ability to prime without competi-
tion from wild-type tRNA3
Lys. This is shown when the priming
efficiency of tRNA3
LysSu1G73A is measured. It has previously
been demonstrated that only the terminal six nucleotides at
the 59 terminus of the HIV PBS are required to be comple-
mentary to the 39-terminal six bases of tRNA3
Lys to initiate
priming of minus-strand strong-stop DNA in vivo, and the al-
teration of a single base within this six-base PBS sequence
prevented the initiation of reverse transcription (24). Our re-
sults with tRNA3
LysSu1G73A support these findings, for while
this tRNA can prime alone with 60% of the efficiency of wild-
type tRNA3
Lys, it competes very poorly with wild-type tRNA3
Lys
for priming reverse transcription. Its ability to function well
alone as a primer probably reflects a tolerance for the single-
base mismatch which is eliminated when wild-type tRNA3
Lys is
also present.
Figures 4 and 5 compare the abilities of wild-type and mu-
tant tRNA3
Lys to prime reverse transcription when heat an-
nealed to the template, while Fig. 6 compares the same abili-
FIG. 3. Dot blot hybridization test of the purity of each tRNALys species shown in Fig. 2, using 32P-end-labeled DNA probes specific for each tRNA.
FIG. 4. Electrophoretic analysis of the abilities of different tRNALys species
to prime the RT-catalyzed synthesis of minus-strand strong-stop cDNA. (A) 1D
PAGE of reverse transcription products. Except for the reaction primed with
tRNA1,2Lys, all reactions were carried out with an excess of synthetic genomic RNA
(2 pmol) over the amount of tRNALys species used as the primer. The major
band in each lane represents full-length minus-strand strong-stop cDNA. Label-
ing of these products was with [a-32P]dCTP. Only the relevant part of the
32P-59-end-labeled fX174 restricted DNA marker band pattern is shown. (B)
Quantitation of the minus-strand strong-stop cDNA synthesized in each lane in
panel A, using phosphor imaging analysis.
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ties in assays using in vivo-placed tRNA3
Lys. Our results clearly
show that when heat annealed, tRNA3
Lys and tRNA3
LysSu1
have equal abilities to prime reverse transcription but that only
wild-type tRNA3
Lys can act as a primer when placement occurs
in vivo. Because total viral RNA is used as the source of primer
tRNA placed onto the template in vivo, the samples used in
Fig. 6 have a ratio of tRNA3
Lys to genomic RNA higher than
that used for in vitro experiments represented in Fig. 4 and 5.
The tRNA/genomic RNA ratio was kept low in the experi-
ments represented in Fig. 4 so as to maximize the detection of
differences in priming ability between wild-type and mutant
tRNA3
Lys when they act alone as primers, and these conditions
were also required for the experiments in both Fig. 4 and 5 so
as to minimize inhibition of reverse transcription by excess
tRNA. However, the inability of tRNA3
LysSu1 to act as a prim-
er when total viral RNA is used as the source of primer/
template is not due to the different set of conditions repre-
sented in Fig. 5 and 6. First, using total viral RNA containing
both mutant and wild-type tRNA3
Lys, we are unable to demon-
strate priming by in vivo-placed tRNA3
LysSu1 even when wild-
type tRNA3
Lys priming is substantially increased as a result of
relieving tRNA-induced inhibition of reverse transcription by
adding excess RT (Fig. 6). Second, the inability of tRNA3
LysSu1
to act as a primer when total viral RNA is used is due not to a
change in reaction conditions but to the manner of placement
on the genome, since as shown in Fig. 7, if the total viral RNA
FIG. 5. Analysis of the abilities of mutant and wild-type tRNA3Lys to compete
with each other for initiating reverse transcription. Reverse transcription was
carried out with 0.5 pmol of synthetic genomic RNA and an equal or excess
amount of total tRNALys as the primer. Reactions were carried out in the
presence of dTTP, dGTP, and [a-32P]dCTP, with dATP being replaced with
ddATP, thereby limiting the DNA extension to six bases. This limited base
extension plus SSCP PAGE allows for the resolution of transcripts synthesized
from mutant and wild-type tRNA3Lys. Panel A or B represents competition
between wild-type tRNA3Lys and either tRNA3LysSu1 or tRNA3LysSu1G73A, re-
spectively.
FIG. 6. Electrophoretic analysis of the ability of tRNA3Lys and tRNA3LysSu1
to initiate reverse transcription, using total viral RNA as the source of primer/
template. Reverse transcription was carried out with increasing concentrations of
RT and equal amounts of total viral RNA (109 copies of genomic RNA per reac-
tion). SVC21.BH10 virus contains wild-type concentrations of tRNA3Lys, while
SVC21.BH10.Lys3 or SVC21.BH10SU1 virions contain either excess tRNA3Lys
or tRNA3LysSu1, respectively. Reactions were carried out in the presence of
dTTP, dGTP, and [a-32P]dCTP, with dATP being replaced with ddATP, thereby
limiting the DNA extension to six bases. This limited base extension plus SSCP
PAGE allows for the resolution of transcripts synthesized from mutant and
wild-type tRNA3Lys, as shown in the two right-hand lanes, representing extensions
of wild-type and mutant tRNA3Lys heat annealed to synthetic genomic RNA.
FIG. 7. Abilities of heat-annealed viral tRNAs to initiate reverse transcrip-
tion. The reaction conditions are the same as for Fig. 6 except that the total viral
RNA (from SVC21.BH10 and SVC21.BH10SU1) was first denatured at 858C
and then annealed back to an excess of synthetic genomic RNA. Exogenous
tRNA3Lys and tRNA3LysSu1 heat annealed to synthetic genomic RNA were run as
markers.
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is heated and tRNA is allowed to reanneal, both wild-type and
mutant tRNAs act as primers for reverse transcription.
The SUU anticodon of tRNA3
Lys has been proposed to in-
teract with an A-rich loop upstream of the PBS (12), and the
inability of in vivo-packaged tRNA3
LysSu1 to prime RT could
be a consequence of its inability to interact with this A-rich
loop. However, we also find that heat-annealed tRNA3
LysSu1
has an equal ability to compete with wild-type tRNA3
Lys for
priming function, and we may ask why this difference exists
between the heat-annealed and in vivo-placed tRNA. Li et al.
have recently found that a deletion of the four A’s in the A-rich
loop does not interfere with in vivo viral replication (14). How-
ever, contrasting results obtained by Wakefield et al. (24) in-
dicate that the A-rich loop is involved in primer tRNA place-
ment. They found that infection of cells with HIV-1 containing
a PBS complementary to tRNAHis rather than tRNA3
Lys results
in an initial low rate of virus replication, followed at later
stages by rates of virus production approaching those of wild-
type virus. The increased viral replication is correlated with
reversion of the tRNAHis PBS to a PBS complementary to
tRNA3
Lys, implying the eventual use of tRNA3
Lys again as the
primer (24). Similar results have been obtained by others using
PBSs complementary to other non-tRNA3
Lys tRNAs (9, 15).
However, when Wakefield et al. changed the A-rich loop such
that it was complementary to the tRNAHis anticodon (23), the
tRNAHis PBS became stabilized in the viral population, and
wild-type viral replication occurred (although some other mu-
tations which may be further required for this stabilization also
arose near the A-rich loop region). This result clearly indicates
a role of the A-rich loop region in allowing tRNAHis to be
stably used as a primer, while the unpublished results of Wain-
berg and colleagues indicate that the A-rich loop is not impor-
tant for reverse transcription and viral replication (22a). The
following model may be proposed to reconcile these disparate
results. The A-loop region may sterically interfere with the
placement of tRNA3
Lys onto the PBS, and under normal con-
ditions, this interference can be removed if the tRNA first
interacts with the loop via its anticodon. This A-rich loop
interference can also be removed either through a deletion in
the loop or through heat denaturation. The model predicts that
removal of the A-rich loop would not affect reverse transcrip-
tion in vivo, but altering this loop to be complementary to
tRNAHis not only would allow tRNAHis to be placed onto the
PBS but also would prevent tRNA3
Lys from being placed onto
the PBS. Heat-annealed tRNA3
LysSu1 would be able to bind
with the same efficiency as wild-type tRNA3
Lys (as a result of
denaturation of the loop), but in vivo-packaged tRNA3
LysSu1
could not overcome the steric hindrance from the A-rich loop.
While this model could explain the seemingly disparate re-
sults discussed above, the relationship between other data and
this model remains to be determined. For example, while Isel
et al. detected an interaction between the A-rich loop and the
tRNA3
Lys anticodon in assays using heat-annealed tRNA3
Lys
(11, 12), we find no difference in the heat-annealed placement
of either wild-type tRNA3
Lys or tRNA3
LysSu1 and therefore
conclude that heat-annealed tRNA3
Lys does not require the
anticodon–A-rich loop interaction. However, it may be that
after annealing and lowering of the reaction temperature,
the heat-annealed primer tRNA3
Lys reestablishes an interac-
tion with the A-rich loop, and this is what was measured by
Isel et al. The role of such a postplacement interaction is
not clear. It may help place the tRNA3
Lys optimally onto the
PBS, but if so, differences in priming between optimal and
suboptimal placement of the primer are not detected in our in
vitro reverse transcription assays primed by wild-type or sup-
pressor tRNALys, nor are differences seen in vivo when wild-
type and A-rich loop-deleted genomic RNAs are used as tem-
plates (14).
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